stockportfolio.pro
Stocks / DNA vs MCTA
DNA vs MCTA
Ginkgo Bioworks Holdings, Inc. and Charming Medical Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ginkgo Bioworks Holdings, Inc. (DNA) | Charming Medical Limited (MCTA) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $170.16M | $6.22M |
| Net income (latest FY) | $-312.76M | $1.20M |
| Revenue growth (5y CAGR) | 17.3% | 32.7% |
| Net margin | -183.8% | 19.3% |
| Return on equity | -61.5% | 2435.0% |
| P/E ratio | — | 419.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DNA — free Open MCTA — freeFrequently asked questions
Which is bigger, DNA or MCTA?
Ginkgo Bioworks Holdings, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, DNA or MCTA?
Over the last five fiscal years, Charming Medical Limited grew revenue faster — 32.7%/yr versus 17.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.